Basic and clinical immunology -3031. The correlation between serum protemics patterns of sTRAIL and CXCL8 with FDG-PET/CT findings in bevacizumab treated colon cancers 
Background
Bevacizumab is a humanized monoclonal antibody developed against vascular endothelial growth factor (VEGF) for the treatment of metastatic colorectal cancer (MCRC). The changes and correlations of sTRAIL and CXCL8 prior to treatment and three months following therapy as well as the corresponding Positron emission tomography (18FDG-PET/CT) results were evaluated.
Methods
The measurements were taken before and after treatment for comparison purposes. The study population comprised 17/29 patients with MCRC, undergoing PET/CT scanning prior to treatment. We were able to perform a follow up PET/CT examination three months after onset of therapy in 15/17 patients.Patients were instructed to fast for at least 6h before an injection of 18F-FDG (5 MBq/kg)(GeminiPET/CTsystem). Images were reconstructed using the maximum-likelihood 3-dimensional algorithm according to standard clinical protocol: 2 iterations,relaxation parameter of 0.05,5-mm,3-dimensional gaussian postfiltering, a4·4·4mm-voxel grid sampling, and attenuation correction based on a low-dose CT scan.All images were visually interpreted by consensus between two experienced nuclear physicians and standardized uptake values(SUV max ) were calculated from the image data.
Results
There were significant changes prior to treatment and three months later for sTRAIL(p=0.0080) and CXCL8 (p=0.0001). Generally, sTRAIL values were increasing during therapy, while a decrease was observed for CXCL8. Correlation analysis was applied to the data and revealed significant correlations for the SUV max in the primary tumor prior to treatment and CXCL8 prior to therapy (p=0.0303). Furthermore, significant correlations were observed for the SUV max and sTRAIL(p=0.0237) as well as CXCL8(p=0.0002) three months after treatment initiation. CXCL8 prior to treatment was also correlated with the SUV three months after onset of treatment (p=0.0072). A significant correlation was noted for one combination of two variables, the SUV max in the metastases and CXCL8 prior to treatment (p=0.0175). These results are supported when we group the SUV max in the metastases following treatment into two groups with SUV max <5 and SUV max >5. There is a significant difference for both groups regarding overall survival, with a lower survival associated with SUV max s exceeding.
Conclusions
This study provides evidence that proteomics patterns of sTRAIL and CXCL8 predict tumor response und survival in MCRC patients treated with bevacizumab and within a high concordance of 18-FDG-PET/CT findings. The high correlation of CXCL8 and FDG uptake in metastases prior to treatment with survival direct to a promising approach to individualize treatment of patients. 
